Leukemia drug breakthrough: study tests tapering strategy to free patients from daily pills

NCT ID NCT05753384

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people with chronic myeloid leukemia (CML) can stop taking their daily targeted therapy (TKI) without the cancer coming back. It compares two approaches: stopping the drug suddenly after a year of normal dosing, versus slowly reducing the dose over a year before stopping. The goal is to see which method helps more patients stay in remission without needing medication, while also reducing side effects and improving quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CH Brive la Gaillarde

    Brive-la-Gaillarde, France

  • CH Versailles

    Versailles, France

  • CHI Creteil

    Créteil, France

  • CHU Limoges

    Limoges, France

  • Centre Léon Bérard

    Lyon, France

  • Ch Annecy

    Annecy, France

  • Ch Bayonne

    Bayonne, France

  • Ch Chambery

    Chambéry, France

  • Ch La Rochelle

    La Rochelle, France

  • Ch Mont de Marsan

    Mont-de-Marsan, France

  • Ch Perigueux

    Périgueux, France

  • Chu Angers

    Angers, France

  • Chu Brest

    Brest, France

  • Chu Lille

    Lille, France

  • Chu Nancy

    Nancy, France

  • Chu Nantes

    Nantes, France

  • Chu Poitiers

    Poitiers, France

  • Chu Tours

    Tours, France

  • Hopital Prive Du Confluent

    Nantes, France

  • Oncopole Toulouse

    Toulouse, France